JPMorgan raised its 2026 and 2027 sales and profit-per-share forecasts, citing Lilly's metabolic business and weight-loss drug pipeline. This supports a brighter outlook, though the forecasts are the bank's estimates, not results Lilly has reported.
Those higher forecasts point to stronger sales and profit if Lilly's metabolic business and drug pipeline deliver. But these are JPMorgan's estimates, not results Lilly has already reported.
Follow Eli Lilly and Company (LLY) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for LLY